Catherine M Viscoli

List of Publications by Year
in descending order

229 papers	38,324 citations	17440 63 h-index	2828 191 g-index
234 all docs	234 docs citations	234 times ranked	23656 citing authors

#	Article	IF	Citations
1	Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep and Breathing, 2023, 27, 669-672.	1.7	10
2	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 135-141.	4.4	29
3	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology,the, 2022, 10, 24-34.	11.4	40
4	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 513-525.	7.1	33
5	Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). American Heart Journal, 2022, 244, 107-115.	2.7	12
6	Efficacy of Dapagliflozin in Black Versus White Patients With HeartÂFailure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64.	4.1	10
7	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 1066-1076.	7.1	28
8	Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. Diabetes, 2022, 71, 812-820.	0.6	5
9	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine, 2022, 43, 101240.	7.1	6
10	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
11	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk inÂDAPA-HF. JACC: Heart Failure, 2022, 10, 104-118.	4.1	5
12	Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3003-e3007.	3.6	12
13	Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes, Obesity and Metabolism, 2022, 24, 1150-1158.	4.4	13
14	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, Obesity and Metabolism, 2022, 24, 1061-1071.	4.4	15
15	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.	4.1	75
16	Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	1.5	2
17	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. Diabetes Research and Clinical Practice, 2022, 186, 109837.	2.8	5
18	Relationship of Dapagliflozin WithÂSerumÂSodium. JACC: Heart Failure, 2022, 10, 306-318.	4.1	10

#	Article	IF	Citations
19	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
20	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, 820-830.	3.9	56
21	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation, 2022, 146, 808-818.	1.6	33
22	Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
23	Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
24	Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080.	4.4	16
25	Empagliflozin treatment effects across categories of baseline <scp>HbA1c</scp>, body weight and blood pressure as an addâ€on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 425-433.	4.4	19
26	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193
27	Characterization and implications of the initial estimated glomerular filtration rate â€˜dipâ€™ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99, 750-762.	5.2	111
28	Association of Baseline Characteristics With Insulin Sensitivity and Î²-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care, 2021, 44, 340-349.	8.6	16
29	Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. Neuro-Oncology Advances, 2021, 3, vdab124.	0.7	3
30	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2021, 23, 632-643.	7.1	24
31	Impact of polyvascular disease with and without coâ€existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of <scp>EMPAâ€REG OUTCOME</scp>. Diabetes, Obesity and Metabolism, 2021, 23, 1173-1181.	4.4	11
32	Effect of dapagliflozin on anaemia in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2021, 23, 617-628.	7.1	57
33	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review, 2021, 16, e11.	2.2	2
34	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINEâ€HF</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1426-1430.	4.4	14
35	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <scp>DAPAâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 601-613.	7.1	33
36	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. Journal of Pharmaceutical Policy and Practice, 2021, 14, 35.	2.4	1

#	Article	IF	Citations
37	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	4.1	75
38	Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007â€“3015. Diabetes Care, 2021, 44, e137-e138.	8.6	0
39	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the <scp>EMPAâ€REG OUTCOME</scp> trial. European Journal of Heart Failure, 2021, 23, 1085-1093.	7.1	23
40	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
41	Treating Diabetes to Prevent Stroke. Stroke, 2021, 52, 1557-1560.	2.0	5
42	A Single Virtual Consult Reduces Severe Hyperglycemia in Patients Admitted with COVID19 Infection. Journal of the Endocrine Society, 2021, 5, A335-A335.	0.2	0
43	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 499.	6.1	120
44	Extreme High Insulin Requirements in Two Non-Diabetic Patients Following Cardiac Transplantation. Journal of the Endocrine Society, 2021, 5, A383-A383.	0.2	0
45	Acute Myeloid Leukemia Leading to Central Diabetes Insipidus. Journal of the Endocrine Society, 2021, 5, A570-A571.	0.2	0
46	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	7.1	195
47	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPAâ€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 2603-2607.	3.1	16
48	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	6.1	12
49	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 2021, 23, 1662-1672.	7.1	36
50	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 669-672.	27.0	0
51	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895.	1.7	14
52	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 2021, 42, 3727-3738.	2.2	125
53	Somatic NF1 mutations in pituitary adenomas: Report of two cases. Cancer Genetics, 2021, 256-257, 26-30.	0.4	1
54	Lessons Learned From Major Clinical Outcomes Trials Involving Sodiumâ€“Glucose Cotransporter 2 Inhibitors. Diabetes Spectrum, 2021, 34, 235-242.	1.0	0

#	Article	IF	Citations
55	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2775-2784.	4.4	12
56	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care, 2021, 44, 586-594.	8.6	50
57	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPAâ€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 4517-4527.	3.1	46
58	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. International Journal of Cardiovascular Imaging, 2021, , 1.	1.5	6
59	Update in Endocrinology. Medical Clinics of North America, 2021, 105, xvii-xviii.	2.5	0
60	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008837.	3.9	21
61	Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, .	2.2	27
62	Comprehensive Genomic Characterization of A Case of Granular Cell Tumor of the Posterior Pituitary Gland: A Case Report. Frontiers in Endocrinology, 2021, 12, 762095.	3.5	4
63	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOMEÂ® trial. European Heart Journal, 2020, 41, 209-217.	2.2	28
64	Reports of Lactic Acidosis Attributed to Metformin, 2015â€“2018. Diabetes Care, 2020, 43, 244-246.	8.6	17
65	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
66	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 141, 90-99.	1.6	244
67	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPAâ€REG OUTCOME trial. European Journal of Heart Failure, 2020, 22, 126-135.	7.1	67
68	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucoseâ€lowering therapy?. Diabetes, Obesity and Metabolism, 2020, 22, 631-639.	4.4	58
69	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2020, 43, 3007-3015.	8.6	45
70	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128
71	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovascular Diabetology, 2020, 19, 200.	6.8	13
72	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 949-959.	11.4	41

#	Article	IF	Citations
73	Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 2335-2347.	4.4	22
74	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care, 2020, 43, 2878-2881.	8.6	20
75	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
76	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 2020, 41, 3402-3418.	2.2	90
77	Adherence to study drug in a stroke prevention trial"?>. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105048.	1.6	3
78	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.	3.9	14
79	Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series. ESC Heart Failure, 2020, 7, 1966-1971.	3.1	19
80	Empagliflozin in Heart Failure. Circulation, 2020, 142, 1028-1039.	1.6	252
81	LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE â€˜EGFR DIPâ€™ IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
82	Efficacy and safety of sodiumâ€“glucose coâ€transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€HF. European Journal of Heart Failure, 2020, 22, 1247-1258.	7.1	29
83	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3025-3035.	3.6	22
84	Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. Cardiovascular Endocrinology and Metabolism, 2020, 9, 56-59.	1.1	20
85	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
86	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	2.2	151
87	Diagnosis and Management of pituitary disease with focus on the role of Magnetic Resonance Imaging. Endocrine, 2020, 68, 489-501.	2.3	7
88	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	4.1	87
89	Association between uric acid levels and cardioâ€renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPAâ€REG OUTCOME. Diabetes, Obesity and Metabolism, 2020, 22, 1207-1214.	4.4	29
90	The authors reply. Kidney International, 2020, 97, 213-214.	5.2	0

#	Article	IF	Citations
91	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPAâ€REG OUTCOME trial. Diabetes, Obesity and Metabolism, 2020, 22, 1141-1150.	4.4	20
92	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes, 2020, 69, 131-LB.	0.6	1
93	Response to Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015â€“2018. Diabetes Care 2020;43:244â€“246. Diabetes Care, 2020, 43, e159-e159.	8.6	0
94	MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D. Journal of the Endocrine Society, 2020, 4, .	0.2	0
95	SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma. Journal of the Endocrine Society, 2020, 4, .	0.2	0
96	The Dapagliflozin And Prevention of Adverseâ€outcomes in Heart Failure (DAPAâ€HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.	7.1	159
97	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. American Journal of Kidney Diseases, 2019, 74, 713-715.	1.9	33
98	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
99	Diabetes prevention and cardiovascular complications. Diabetologia, 2019, 62, 2161-2162.	6.3	4
100	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2019, 140, 1463-1476.	1.6	279
101	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOMEÂ® trial. Age and Ageing, 2019, 48, 859-866.	1.6	79
102	FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later. Diabetes, Obesity and Metabolism, 2019, 21, 1073-1078.	4.4	33
103	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e53-e55.	8.6	27
104	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes and Vascular Disease Research, 2019, 16, 133-143.	2.0	155
105	Understanding Contemporary Use of Thiazolidinediones. Circulation: Heart Failure, 2019, 12, e005855.	3.9	35
106	Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?. Circulation, 2019, 139, 2383-2385.	1.6	1
107	Evidence supports prediabetes treatment. Science, 2019, 364, 341-342.	12.6	18
108	A trial to evaluate the effect of the sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	7.1	264

#	Article	IF	Citations
109	Analysis from the EMPA-REG OUTCOMEÂ® trialÂindicates empagliflozin may assist in preventingÂtheÂprogression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney International, 2019, 96, 489-504.	5.2	77
110	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. Circulation, 2019, 139, 1458-1460.	1.6	49
111	Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. Journal of Diabetes and Its Complications, 2019, 33, 462-464.	2.3	3
112	An Error in An Old Paper Illustrates the Need for Data/Code Archives - Author response. Journal of Clinical Epidemiology, 2019, 107, 129.	5.0	0
113	Pioglitazone Therapy in Patients With Stroke and Prediabetes. JAMA Neurology, 2019, 76, 526.	9.0	83
114	Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. Stroke, 2019, 50, 713-717.	2.0	7
115	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. Diabetes, Obesity and Metabolism, 2019, 21, 720-725.	4.4	15
116	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 2019, 139, 366-375.	1.6	32
117	Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 2019, 21, 1121-1127.	4.4	40
118	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation, 2019, 139, 1384-1395.	1.6	205
119	Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke, 2019, 50, 95-100.	2.0	9
120	Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease. International Journal of Stroke, 2019, 14, 639-645.	5.9	5
121	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open, 2019, 9, e029098.	1.9	3
122	Hypoglycemia in type 2 diabetes: understanding patientsâ€™ and physiciansâ€™ knowledge and experience. Endocrine, 2018, 60, 435-444.	2.3	6
123	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOMEÂ® trial. European Heart Journal, 2018, 39, 363-370.	2.2	199
124	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. Endocrinology and Metabolism Clinics of North America, 2018, 47, 137-152.	3.2	7
125	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditorsâ€™ Expert Forum. Diabetes Care, 2018, 41, 14-31.	8.6	338
126	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney International, 2018, 94, 26-39.	5.2	262

#	Article	IF	Citations
127	Empagliflozin in women with type 2 diabetes and cardiovascular disease â€“ an analysis of EMPA-REG OUTCOMEÂ®. Diabetologia, 2018, 61, 1522-1527.	6.3	49
128	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€“Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American Heart Journal, 2018, 202, 39-48.	2.7	15
129	Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. Neuroepidemiology, 2018, 50, 137-143.	2.3	7
130	Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke. Circulation, 2018, 137, 455-463.	1.6	45
131	Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 21-27.	1.9	7
132	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation, 2018, 137, 119-129.	1.6	347
133	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2018, 41, 356-363.	8.6	534
134	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation, 2018, 137, 405-407.	1.6	131
135	Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. Diabetes Care, 2018, 41, e4-e5.	8.6	143
136	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation, 2018, 138, 1599-1601.	1.6	28
137	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	13.7	70
138	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. Circulation, 2018, 138, 1904-1907.	1.6	117
139	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Journal of the American Society of Nephrology: JASN, 2018, 29, 2755-2769.	6.1	148
140	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. Diabetes Care, 2018, 41, 1121-1124.	8.6	43
141	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMEÂ® randomised trial. Diabetologia, 2018, 61, 1712-1723.	6.3	88
142	Levothyroxine pseudo-malabsorption: testing and treatment in the outpatient setting. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 217-222.	3.2	8
143	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). American Heart Journal, 2018, 203, 25-29.	2.7	29
144	SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOMEÂ® TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i487-i487.	0.7	0

#	Article	IF	Citations
145	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation, 2018, 138, 1210-1220.	1.6	42
146	Impact of treatment with pioglitazone on stroke outcomes: A realâ€world database analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2140-2147.	4.4	18
147	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	27.0	205
148	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications, 2018, 32, 1035-1039.	2.3	3
149	Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia, 2018, 61, 2118-2125.	6.3	127
150	Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-3237.	3.6	62
151	The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia, 2017, 60, 395-398.	6.3	34
152	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation, 2017, 135, 1882-1893.	1.6	53
153	A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion, 2017, 33, 1853-1860.	1.9	10
154	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke, 2017, 48, 1218-1225.	2.0	112
155	Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684â€“1692. Diabetes Care, 2017, 40, e47-e48.	8.6	1
156	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurology, 2017, 74, 1319.	9.0	21
157	Response by Young et al to Letters Regarding Article, â€œCardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitusâ€• Circulation, 2017, 136, 1567-1568.	1.6	1
158	Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia, 2017, 60, 2534-2535.	6.3	24
159	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry ^{Â®}. Journal of the American Heart Association, 2017, 6, .	3.7	21
160	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDRÂ® Research to Practice project. European Journal of Preventive Cardiology, 2017, 24, 1637-1645.	1.8	109
161	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. Diabetes Care, 2017, 40, 1128-1132.	8.6	32
162	Metformin: clinical use in type 2 diabetes. Diabetologia, 2017, 60, 1586-1593.	6.3	349

#	Article	IF	Citations
163	Response by Zinman et al to Letter Regarding Article, â€œEmpagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Riskâ€. Stroke, 2017, 48, e256-e257.	2.0	0
164	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 610-621.	11.4	301
165	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006â€“2013. Diabetes Care, 2017, 40, 468-475.	8.6	249
166	Heart failure outcomes in clinical trials of glucoseâ€lowering agents in patients with diabetes. European Journal of Heart Failure, 2017, 19, 43-53.	7.1	91
167	Current Therapies for the Medical Management of Diabetes. Obstetrics and Gynecology, 2016, 127, 780-794.	2.4	18
168	A Diagnostic Score for Insulin Resistance in Nondiabetic Patients with Ischemic Stroke or Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1705-1712.	1.6	2
169	Improving Type 2 Diabetes Patient Health Outcomes with Individualized Continuing Medical Education for Primary Care. Diabetes Therapy, 2016, 7, 473-481.	2.5	5
170	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care, 2016, 39, 1684-1692.	8.6	60
171	The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone. Journal of Diabetes, 2016, 8, 607-609.	1.8	4
172	Minimization of Hypoglycemia as an Adverse Event During Insulin Infusion: Further Refinement of the Yale Protocol. Diabetes Technology and Therapeutics, 2016, 18, 480-486.	4.4	16
173	Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience. Circulation, 2016, 134, 1405-1408.	1.6	27
174	Implications of the EMPA-REG Trial for Clinical Care and Research. Current Diabetes Reports, 2016, 16, 131.	4.2	7
175	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1799-1802.	27.0	120
176	Taking care of volunteers in a stroke trial: a new assisted-management strategy. Stroke and Vascular Neurology, 2016, 1, 108-114.	3.3	1
177	Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. Diabetes Care, 2016, 39, e99-e101.	8.6	29
178	Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetesâ€”2016. Diabetes Care 2016;39(Suppl. 1):S52â€“S59. Diabetes Care, 2016, 39, e88-e89.	8.6	15
179	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 323-334.	27.0	2,809
180	SGLT2 inhibitors in the management of type 2 diabetes. Endocrine, 2016, 53, 364-372.	2.3	64

#	Article	IF	Citations
181	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 374, 1321-1331.	27.0	877
182	Approach to diabetes management in patients with CVD. Trends in Cardiovascular Medicine, 2016, 26, 165-179.	4.9	38
183	Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. SAGE Open Medicine, 2015, 3, 205031211456847.	1.8	25
184	Hyperglycemia grand rounds: descriptive findings of outcomes from a continuing education intervention to improve glycemic control and prevent hypoglycemia in the hospital setting. Hospital Practice (1995), 2015, 43, 270-276.	1.0	3
185	Metabolic Management during Critical Illness: Glycemic Control in the ICU. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 859-869.	2.1	23
186	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2015, 58, 429-442.	6.3	598
187	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: Results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. American Heart Journal, 2015, 170, 753-759.e2.	2.7	5
188	How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?. Diabetes Research and Clinical Practice, 2015, 108, 179-186.	2.8	17
189	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 260-267.	2.2	16
190	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research, 2015, 12, 90-100.	2.0	333
191	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140â€“149. Diabetes Care, 2015, 38, e128-e129.	8.6	25
192	Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2015, 9, 1227-1235.	2.2	13
193	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128.	27.0	8,841
194	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 140-149.	8.6	2,326
195	Glycemic Targets. Medical Clinics of North America, 2015, 99, 47-67.	2.5	13
196	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. BMJ Open Diabetes Research and Care, 2014, 2, e000046.	2.8	9
197	Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial. American Heart Journal, 2014, 168, 823-829.e6.	2.7	42
198	Litigation Seeking Access to Data From Ongoing Clinical Trials. JAMA Internal Medicine, 2014, 174, 1502.	5.1	1

#	Article	IF	Citations
199	The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy. Diabetes Care, 2014, 37, 1924-1930.	8.6	54
200	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMEâ„¢). Cardiovascular Diabetology, 2014, 13, 102.	6.8	198
201	Metformin in Patients With Type 2 Diabetes and Kidney Disease. JAMA - Journal of the American Medical Association, 2014, 312, 2668.	7.4	474
202	National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. JAMA Internal Medicine, 2014, 174, 1116.	5.1	324
203	Decade-Long Trends in Mortality Among Patients With and Without Diabetes Mellitus at a Major Academic Medical Center. JAMA Internal Medicine, 2014, 174, 1187.	5.1	16
204	Using the Glucometrics Website to Benchmark ICU Glucose Control Before and After the NICE-SUGAR Study. Journal of Diabetes Science and Technology, 2014, 8, 918-922.	2.2	6
205	The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study. Journal of Critical Care, 2014, 29, 1052-1056.	2.2	19
206	Clitoral Epidermoid Cyst Presenting as Pseudoclitoromegaly of Pregnancy. AJP Reports, 2013, 03, 057-062.	0.7	4
207	Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents. Journal of Diabetes and Its Complications, 2012, 26, 333-338.	2.3	8
208	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care, 2012, 35, 1364-1379.	8.6	3,077
209	Diagnosis of Diabetes. New England Journal of Medicine, 2012, 367, 542-550.	27.0	172
210	Chromium Picolinate for the Prevention of Type 2 Diabetes. Treatment Strategies Diabetes, 2011, 3, 34-40.	0.0	1
211	New Drugs for the Treatment of Diabetes. Circulation, 2008, 117, 574-584.	1.6	181
212	Metformin therapy in patients with Type 2 diabetes complicated by heart failure. American Heart Journal, 2007, 154, e45.	2.7	9
213	Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes. Endocrinology and Metabolism Clinics of North America, 2007, 36 Suppl 2 Incretin, 2-17.	3.2	0
214	Management of Hyperglycemia in the Hospital Setting. New England Journal of Medicine, 2006, 355, 1903-1911.	27.0	354
215	Treatment of diabetes in the elderly. Postgraduate Medicine, 2005, 118, 19-29.	2.0	26
216	Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology, 2005, 192, 387-393.	1.3	92

#	Article	IF	Citations
217	Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project. Diabetes Care, 2005, 28, 1680-1689.	8.6	99
218	The Prevention of Type 2 Diabetes Mellitus. Endocrinology and Metabolism Clinics of North America, 2005, 34, 199-219.	3.2	53
219	Management of hypercalcemia. Postgraduate Medicine, 2004, 115, 27-36.	2.0	18
220	Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management. Current Treatment Options in Neurology, 2004, 6, 443-450.	1.8	46
221	Diabetes mellitus in pregnancy. Obstetrics and Gynecology Clinics of North America, 2004, 31, 907-933.	1.9	39
222	Understanding hypercalcemia. Postgraduate Medicine, 2004, 115, 69-76.	2.0	63
223	Metformin. Drugs, 2003, 63, 1879-1894.	10.9	272
224	Oral Antihyperglycemic Therapy for Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2002, 287, 360.	7.4	922
225	Type 2 diabetes therapy. Postgraduate Medicine, 2002, 111, 83-95.	2.0	6
226	Glycemic Management of Diabetes in the Perioperative Setting. International Anesthesiology Clinics, 2002, 40, 77-93.	0.8	7
227	The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle and Nerve, 2001, 24, 1229-1231.	2.2	229
228	Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer, 2001, 91, 443-454.	4.1	206
229	The Stroke Prognosis Instrument II (SPI-II). Stroke, 2000, 31, 456-462.	2.0	184